The significance of oral L-carnitine administration in liver cirrhotic patients -a comparative study of treatment efficacy and safety between L-carnitine and lactulose in patients with minimal hepatic encephalopathy-

The significance of oral L-carnitine administration in liver cirrhotic patients -a comparative study of treatment efficacy and safety between L-carnitine and lactulose in patients with minimal hepatic encephalopathy- - The significance of oral L-carnitine administration in liver cirrhotic patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021808

Enrollment

Registered

2016-05-01

Start date

2016-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cirrhosis

Interventions

The oral L-carnitine administration is performed. The oral lactulose administration is performed.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Those who are more than 20 years old, those who have performance status 0 or 1, those who have decompensated cirrhosis with minimal hepatic encephalopathy, or those who have consent about this study are included in this study.

Exclusion criteria

Exclusion criteria: Those who have pregnancy, those who can not continue the treatment because of several diseases such as cancer therapy, or those who have difficulty for the enrollment of this study are excluded in this study.

Design outcomes

Primary

Measure	Time frame
A comparative study about the ameliorated rate of MHE	—

Countries

Japan

Contacts

Public ContactHiroki Hayashi

Kobe University Hospital Division of Gastroenterology

hhayashi@med.kobe-u.ac.jp078-382-6305

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026